Sunshine Biopharma Inc. - Common stock (NQ:SBFM)

0.4302 -0.2363 (-35.45%)

Delayed Quote Updated: 1:40 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sunshine Biopharma Inc. - Common stock

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

What's going on in today's pre-market session ↗

April 21, 2025

As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

Via Chartmill

Sunshine Biopharma Launches Everolimus In Canada, an Oncology Drug with an Estimated Global Market of $2.5 Billion

April 21, 2025

Via ACCESS Newswire

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

April 21, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

April 17, 2025

Via Benzinga

BioMedNewsBreaks — Sunshine Biopharma Inc. (NASDAQ: SBFM) Secures $2.46M in Registered Direct

April 03, 2025

Via Investor Brand Network

Sunshine Biopharma Inc. Announces Closing of $2.46 Million Registered Direct Offering

April 03, 2025

Via ACCESS Newswire

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

April 03, 2025

Via Benzinga

Sunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules

April 02, 2025

Via ACCESS Newswire

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

April 02, 2025

Via Benzinga

Sunshine Biopharma Stock Shoots Higher On Encouraging Data From mRNA-Based Liver Cancer Drug ↗

April 02, 2025

Sunshine Biopharma's K1.1 mRNA-LNP shows promise for HCC treatment in mice, while its 2024 revenue surged 45% to $34.9 million.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

April 02, 2025

Via Benzinga

Sunshine Biopharma Announces Positive Results of mRNA Therapy for Cancer

April 02, 2025

Via ACCESS Newswire

US Stock Futures Slip Ahead Of 'Liberation Day' Tariffs Announcement: Expert Points To Uncertainty Amid Higher Risk Premia ↗

April 02, 2025

U.S. stock futures slipped on Wednesday after a mixed session on Tuesday. Futures of major benchmark indices were lower in premarket trading.

Via Benzinga

Why Sportsman's Warehouse Shares Are Trading Higher By Around 39%; Here Are 20 Stocks Moving Premarket ↗

April 02, 2025

Via Benzinga

Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year

April 01, 2025

Via ACCESS Newswire

Sunshine Biopharma Expands Presence in the $53.9 Billion Global Antibiotics Market with the Acquisition of Marketing Rights for Two New Antibiotics in Canada

March 24, 2025

Via ACCESS Newswire

Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million Market

March 10, 2025

Via ACCESS Newswire

Sunshine Biopharma Expands Its Product Line to 69 Generic Prescription Drugs by Launching Olanzapine and Olanzapine ODT

January 21, 2025

Via ACCESS Newswire

Sunshine Biopharma Announces the Appointment of New Chief Commercial Officer

January 15, 2025

Via ACCESSWIRE

Sunshine Biopharma Announces Novel Inhibitor for Sars Coronavirus

December 09, 2024

Via ACCESSWIRE

Sunshine Biopharma Launches a New Generic Prescription Drug

December 04, 2024

Via ACCESSWIRE

Sunshine Biopharma Announces Breakthrough Research Results on the Company’s K1.1 mRNA Product as a Novel Therapeutic Agent for Human Hepatocellular Carcinoma

December 02, 2024

Via ACCESSWIRE

Sunshine Biopharma Launches a New Generic Prescription Drug

November 22, 2024

Via ACCESSWIRE

Sunshine Biopharma Reports 2024 Third Quarter Results: Year-To-Date Revenues Up 54%

November 06, 2024

Via ACCESSWIRE

Sunshine Biopharma Launches Two New Generic Prescription Drugs

September 26, 2024

Via ACCESSWIRE

New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth

September 04, 2024

EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:NVAX),(NASDAQ:RGNX),(NASDAQ:BNTX),(NYSE:ABBV) EQNX::TICKER_END

Via FinancialNewsMedia

Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031

September 04, 2024

EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:MRNA),(NYSE:PFE),(NASDAQ:VIR),(NASDAQ:INO) EQNX::TICKER_END

Via FinancialNewsMedia

New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth

September 04, 2024

From FN Media Group LLC

Via GlobeNewswire

SUNSHINE BIOPHARMA ANNOUNCES PUBLICATION OF SIGNIFICANT CORONAVIRUS RESEARCH RESULTS IN THE JOURNAL OF MEDICINAL CHEMISTRY

September 04, 2024

Current Test Positivity Rate for Coronavirus Infection in the U.S. is 18% Development of a novel antiviral compound, XR8-23 (Compound 10), targeting SARS-CoV-2 papain-like protease (PLpro) with both...

Via FinancialNewsMedia

Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031

September 04, 2024

From FN Media Group LLC

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.